These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36892733)

  • 1. Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.
    Tanner CM; Caroff SN; Cutler AJ; Lenderking WR; Shalhoub H; Pagé V; Franey EG; Serbin M; Yonan C
    J Patient Rep Outcomes; 2023 Mar; 7(1):21. PubMed ID: 36892733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.
    Caroff SN; Yeomans K; Lenderking WR; Cutler AJ; Tanner CM; Shalhoub H; Pagé V; Chen J; Franey E; Yonan C
    J Clin Psychopharmacol; 2020; 40(3):259-268. PubMed ID: 32332461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia.
    Rekhi G; Tay J; Lee J
    J Psychopharmacol; 2022 Feb; 36(2):183-190. PubMed ID: 34979813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation.
    Farber RH; Stull DE; Witherspoon B; Evans CJ; Yonan C; Bron M; Dhanda R; Jen E; Brien CO'
    J Patient Rep Outcomes; 2024 Jan; 8(1):2. PubMed ID: 38175450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study.
    Cutler AJ; Caroff SN; Tanner CM; Shalhoub H; Lenderking WR; Pagé V; Franey E; Yonan C
    J Am Psychiatr Nurses Assoc; 2023; 29(5):389-399. PubMed ID: 34154444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact-Tardive Dyskinesia (Impact-TD) Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia.
    Jackson R; Brams MN; Carlozzi NE; Citrome L; Fritz NE; Hoberg AR; Isaacson SH; Kane JM; Kumar R
    J Clin Psychiatry; 2022 Nov; 84(1):. PubMed ID: 36449471
    [No Abstract]   [Full Text] [Related]  

  • 10. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia.
    McEvoy J; Gandhi SK; Rizio AA; Maher S; Kosinski M; Bjorner JB; Carroll B
    Qual Life Res; 2019 Dec; 28(12):3303-3312. PubMed ID: 31435866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
    Hauser RA; Barkay H; Wilhelm A; Wieman M; Savola JM; Gordon MF
    Parkinsonism Relat Disord; 2022 Apr; 97():47-51. PubMed ID: 35299070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.
    Caroff SN; Leong SH; Roberts CB; Berkowitz RM; Campbell EC
    J Clin Psychopharmacol; 2020; 40(4):373-380. PubMed ID: 32639290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States.
    Jain R; Ayyagari R; Goldschmidt D; Zhou M; Finkbeiner S; Leo S
    J Clin Psychiatry; 2023 Apr; 84(3):. PubMed ID: 37022752
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
    Apud JA; Egan MF; Wyatt RJ
    Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.
    Macaluso M; Flynn A; Preskorn S
    J Psychiatr Pract; 2016 May; 22(3):203-20. PubMed ID: 27123800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis.
    Barer Y; Ribalov R; Yaari A; Maor R; Arow Q; Logan J; Chodick G; Arkadir D; Eitan R
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):454-460. PubMed ID: 36018237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cross-Sectional Study on the Characteristics of Tardive Dyskinesia in Patients with Chronic Schizophrenia.
    Huang Y; Pan L; Teng F; Wang G; Li C; Jin L
    Shanghai Arch Psychiatry; 2017 Oct; 29(5):295-303. PubMed ID: 29276353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.